Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus

Oncology Reports

Volumn 27, Issue 4, 2012, Pages 971-978

  You, Liangshun ^a   Wang, Ying ^a   Jin, Yingming ^a   Qian, Wenbin ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Cisplatin; HeLa cell; HT 29 cells; Mcl 1; Oncolytic adenovirus; Synergy

Indexed keywords

CASPASE; CISPLATIN; CRYSTAL VIOLET; ONCOLYTIC ADENOVIRUS; PROTEIN BCL 2; PROTEIN MCL 1; RHODAMINE 123; SG 511; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; COLON CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME REGULATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VITRO STUDY; MITOCHONDRIAL MEMBRANE POTENTIAL; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

ADENOVIRIDAE; ADENOVIRUS E1B PROTEINS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FLOW CYTOMETRY; HELA CELLS; HT29 CELLS; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICROSCOPY, FLUORESCENCE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 84863075692     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.1636     Document Type: Article

References (53)

1. Kirn D, Martuza RL and Zwiebel J: Replication-selective virotherapy for cancer: biological principles, risk management and future directions. Nat Med 7: 781-787, 2001. (Pubitemid 32691631)
2. Chu RL, Post DE, Khuri FR and Van Meir EG: Use of replicating oncolytic adenoviruses in combination therapy for cancer. Clin Cancer Res 10: 5299-5312, 2004. (Pubitemid 39100464)
3. Bischoff JR, Kirn DH, Williams A, et al: An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274: 373-376, 1996. (Pubitemid 26353341)
4. Ganly I, Kirn D, Eckhardt G, et al: A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. Clin Cancer Res 6: 798-806, 2000. (Pubitemid 30159332)
5. Conrad C, Miller CR, Ji Y, et al: Delta24-hyCD adenovirus suppresses glioma growth in vivo by combining oncolysis and chemosensitization. Cancer Gene Ther 12: 284-294, 2005. (Pubitemid 40315188)
6. Fukuda K, Abei M, Ugai H, Kawashima R, Seo E, Wakayama M, Murata T, Endo S, Hamada H, Hyodo I and Yokoyama KK: E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer. Cancer Gene Ther 16: 126-136, 2009.
7. Douglas JT, Kim M, Sumerel LA, Carey DE and Curiel DT: Efficient oncolysis by a replicating adenovirus (ad) in vivo is critically dependent on tumor expression of primary ad receptors. Cancer Res 61: 813-817, 2001. (Pubitemid 32174383)
8. Nilsson M, Ljungberg J, Richter J, et al: Development of an adenoviral vector system with adenovirus serotype 35 tropism; efficient transient gene transfer into primary malignant hematopoietic cells. J Gene Med 6: 631-641, 2004. (Pubitemid 40228079)
9. Stone D, Ni S, Li ZY, et al: Development and assessment of human adenovirus type 11 as a gene transfer vector. J Virol 79: 5090-5104, 2005. (Pubitemid 40464259)
10. Kawakami Y, Li H, Lam JT, Krasnykh V, Curiel DT and Blackwell JL: Substitution of the adenovirus serotype 5 knob with a serotype 3 knob enhances multiple steps in virus replication. Cancer Res 63: 1262-1269, 2003. (Pubitemid 36348704)
11. Jin J, Liu H, Yang C, et al: Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Mol Cancer Ther 5: 1387-1397, 2009.
12. Wang G, Li G, Liu H, et al: E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies. J Gene Med 11: 477-485, 2009.
13. Wohlfahrt ME, Beard BC, Lieber A and Kiem HP: A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. Cancer Res 67: 8783-8790, 2007. (Pubitemid 47437454)
14. Raki M, Särkioja M, Desmond RA, et al: Oncolytic adenovirus Ad5/3-delta24 and chemotherapy for treatment of orthotopic ovarian cancer. Gynecol Oncol 108: 166-172, 2008. (Pubitemid 350299441)
15. Raki M, Kanerva A, Ristimaki A, et al: Combination of gemcitabine and Ad5/3-Delta24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer. Gene Ther 12: 1198-1205, 2005. (Pubitemid 41136314)
16. Liu D, Kojima T, Ouchi M, et al: Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer. Mol Cancer Ther 8: 980-987, 2009.
17. Zhang Y, Qin X, Zhang Y, et al: Combination of ZD55-MnSOD therapy with 5-FU enhances antitumor efficacy in colorectal cancer. J Cancer Res Clin Oncol 134: 219-226, 2008. (Pubitemid 350234067)
18. Yoon AR, Kim JH, Lee YS, et al: Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin. Hum Gene Ther 17: 379-390, 2006.
19. Fujiwara T, Kagawa S, Kishimoto H, et al: Enhanced antitumor efficacy of telomerase-selective oncolytic adenoviral agent OBP-401 with docetaxel: preclinical evaluation of chemovirotherapy. Int J Cancer 119: 432-440, 2006.
20. Sagawa T, Yamada Y, Takahashi M, et al: Treatment of hepatocellular carcinoma by AdAFPep/rep, AdAFPep/p53, and 5-fluorouracil in mice. Hepatology 48: 828-840, 2008.
21. Quirin C, Mainka A, Hesse A and Nettelbeck DM: Combining adenoviral oncolysis with temozolomide improves cell killing of melanoma cells. Int J Cancer 121: 2801-2807, 2007. (Pubitemid 350136430)
22. Lun XQ, Jang JH, Tang N, et al: Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res 15: 2777-2788, 2009.
23. Cheong SC, Wang Y, Meng JH, et al: E1A-expressing adenoviral E3B mutants act synergistically with chemotherapeutics in immunocompetent tumor models. Cancer Gene Ther 15: 40-50, 2008. (Pubitemid 350261299)
24. Khuri FR, Nemunaitis J, Ganly I, et al: A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 6: 879-885, 2000. (Pubitemid 30644745)
25. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA and McCarty TM: A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). Ann Surg Oncol 7: 588-592, 2000.
26. Galanis E, Okuno SH, Nascimento AG, et al: Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 12: 437-445, 2005. (Pubitemid 40394296)
27. Xia ZJ, Chang JH, Zhang L, et al: Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus. Ai Zheng 23: 1666-1670, 2004 (In Chinese).
28. Reed JC: Mechanisms of apoptosis. Am J Pathol 157: 1415-1430, 2000.
29. Qian W, Liu J, Tong Y, et al: Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis. Leukemia 22: 361-369, 2008. (Pubitemid 351250541)
30. Kanerva A, Zinn KR, Chaudhuri TR, et al: Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 8: 449-458, 2003. (Pubitemid 37167933)
31. Reddy PS, Ganesh S and Yu DC: Enhanced gene transfer and oncolysis of head and neck cancer and melanoma cells by fiber chimeric oncolytic adenoviruses. Clin Cancer Res 12: 2869-2878, 2006.
32. Hall K, Blair Zajdel ME and Blair GE: Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy. Biochem J 431: 321-336, 2010.
33. Fishelson Z, Donin N, Zell S, Schultz S and Kirschfink M: Obstacles to cancer immunotherapy: expression of membrane complement regulatory proteins (mCRPs) in tumors. Mol Immunol 40: 109-123, 2003. (Pubitemid 36959821)
34. Thorsteinsson L, O'Dowd GM, Harrington PM and Johnson PM: The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. APMIS 106: 869-878, 1998. (Pubitemid 28468843)
35. Tuve S, Wang H, Ware C, et al: A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J Virol 80: 12109-12120, 2006. (Pubitemid 44904362)
36. Stoff-Khalili MA, Stoff A, Rivera AA, et al: Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biol Ther 4: 1203-1210, 2005.
37. Go RS and Adjei AA: Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 17: 409-422, 1999. (Pubitemid 29022420)
38. Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7: 573-584, 2007.
39. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003. (Pubitemid 37487159)
40. Takakura M, Nakamura M, Kyo S, et al: Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination. Cancer Gene Ther 17: 11-19, 2010.
41. Pan Q, Liu B, Liu J, Cai R, Wang Y and Qian C: Synergistic induction of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying TRAIL. Mol Cell Biochem 304: 315-323, 2007. (Pubitemid 47456880)
42. Wu YM, Zhang KJ, Yue XT, et al: Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24. Acta Pharmacol Sin 30: 467-477, 2009.
43. Baird SK, Aerts JL, Eddaoudi A, Lockley M, Lemoine NR and McNeish IA: Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene 27: 3081-3090, 2008. (Pubitemid 351693172)
44. Green DR and Kroemer G: The pathophysiology of mitochondrial cell death. Science 305: 626-629, 2004. (Pubitemid 39006738)
45. Heiser D, Labi V, Erlacher M and Villunger A: The Bcl-2 protein family and its role in the development of neoplastic disease. Exp Gerontol 39: 1125-1135, 2004. (Pubitemid 39024362)
46. Kuwana T, Bouchier-Hayes L, Chipuk JE, et al: BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17: 525-535, 2005. (Pubitemid 40269117)
47. Chipuk JE, Fisher JC, Dillon CP, Kriwacki RW, Kuwana T and Green DR: Mechanism of apoptosis induction by inhibition of the anti-apoptotic BCL-2 proteins. Proc Natl Acad Sci USA 105: 20327-20332, 2008.
48. Green DR: At the gates of death. Cancer Cell 9: 328-330, 2006.
49. Zhuang J and Brady HJ: Emerging role of Mcl-1 in actively counteracting BH3-only proteins in apoptosis. Cell Death Differ 13: 1263-1267, 2006. (Pubitemid 44057456)
50. Zhang H, Guttikonda S, Roberts L, et al: Mcl-1 is critical for survival in a subgroup of non-small cell lung cancer cell lines. Oncogene 30: 1963-1968, 2011.
51. Chen W, Bai L, Wang X, Xu S, Belinsky SA and Lin Y: Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 77: 416-423, 2010.
52. Nijhawan D, Fang M, Traer E, et al: Elimination of Mcl-1 is required for the initiation of apoptosis following ultraviolet irradiation. Genes Dev 17: 1475-1486, 2003. (Pubitemid 36734705)
53. Henderson-Jackson EB, Helm J, Ghayouri M, et al: Correlation between Mcl-1 and pAKT protein expression in colorectal cancer. Int J Clin Exp Pathol 3: 768-774, 2010.